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Introduction
Effective and widespread cervical cancer screening has 
greatly reduced cervical cancer incidence and related 
morbidity and mortality1. The most commonly used cervical 
cancer screening method worldwide is a Pap test, which 
involves the collection of  cervical cells for examination 
under a microscope by a cytopathologist.  Pap testing detects 
abnormal cells in the cervix and enables early detection 
and treatment of  cervical cancer1. However, Pap screening 
programs have low feasibility in limited-resource settings 
owing to a lack of  infrastructure and trained personnel, 
limited health budgets and competing healthcare priorities2,3. 
To address these barriers, some national screening programs 
use alternatives to traditional cytology (Pap testing), such as 
visual inspection of  the cervix with acetic acid (VIA). VIA 
involves unaided (naked eye) inspection of  the cervix after 
application of  acetic acid to identify abnormal tissue. While 
VIA eliminates some constraints of  Pap testing, such as cost 
and need for multiple visits, there can be high variability by 
provider in the quality of  VIA screening4–6. 
DNA testing for human papillomavirus (HPV) offers 
an accurate alternative to VIA. The WHO recommends 
hr-HPV DNA testing as the primary cervical cancer 
screening approach in places where Pap testing has not 
been established7. Similar to other screening methods, 
cervical samples are typically gathered by a clinician during 
the course of  a pelvic examination, but samples can also 
be self-collected by women themselves with a swab. WHO 
recommends screening with an HPV test and treatment over 
screening with VIA and treatment where feasible7. HPV 
testing is also recommended as first line screening followed 
by VIA and treatment7. 
When successfully introduced, self-collection of  samples for 
HPV testing can increase screening for hard to reach women 
or women who do not come in for screening tests8–11. Self-
collected samples have been shown to perform comparably 
to clinician-collected samples, but published findings suggest 
that the population and method of  collection or testing are 
important to consider when assessing the utility of  self-
collected samples12–15.
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The World Health Organization (WHO) recently endorsed human papillomavirus (HPV) testing as a cervical cancer screening method 
in countries without established programs. Self-collection for HPV testing may be an effective way to expand screening. Our objective 
was to assess the feasibility, validity, and acceptability of  self-collection for HPV testing in a population of  care-seeking, unscreened 
women in rural Malawi. 
Methods
We enrolled women reporting to a rural Malawian clinic from January to August 2015. Participants were offered the option to self-
collect a vaginal sample and the study clinician collected a cervical sample for HPV testing. Using the clinician-collected sample as the 
reference standard, we calculated a kappa statistic, sensitivity, and specificity by hr-HPV type. Participants also received a brief  survey 
assessing acceptability of  the procedure. 
Results
Among the 199 enrolled women, 22% had any high risk-HPV. Comparing self- and clinician-collected samples for HPV testing, we 
found generally high agreement (κ = 0.66-0.90) and high specificity (98%-100%), but varied sensitivity (50%-91%) for different types 
of  hr-HPV. We also found that self-collection was acceptable, with 98% of  women reporting it was easy to do and 99% reporting 
willingness to do so again. 
Conclusions
WHO guidelines recommend that treatment is available immediately after a positive screening test for clinic-based cervical cancer 
screening programs. Our findings demonstrate that self-collection of  samples for HPV testing is a feasible and acceptable method of  
cervical cancer screening in this rural Malawian population. High agreement between the self- and clinician-collected samples and high 
levels of  acceptability among women in the study suggest that self-collection of  vaginal samples for HPV testing may be effectively 
incorporated into screening programs among rural, largely unscreened populations.
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type of  hr-HPV by clinician-collected sample (Table 2). Six 
women were infected with multiple HPV types: one woman 
tested positive for HPV 16, HPV 18/45, and additional hr-
HPV type(s), 4 women had both HPV 18/45 and additional 
hr-HPV type(s), and one woman had HPV 16 and additional 
hr-HPV type(s). 
Agreement between clinician-collected and self-
collected samples
We found high agreement between HPV results from self- 
and clinician-collected samples as measured by the kappa 
statistic, which measures agreement beyond chance alone. 
The highest agreement between self- and clinician-collected 
samples was for HPV 18/45 (κ = 0. 90). The agreement 
between self- and clinician-collected samples for any type 
of  hr-HPV and the additional hr-HPV types were similar 
(κ=0.77, κ=0.74; Table 3). Overall compared to clinician-
collected samples, self-collected samples were highly 
specific and varied in sensitivity by type of  HPV (Table 3). 
Whereas specificity was 98-100% depending on hr-HPV 
type, sensitivity was poorer; we found the highest sensitivity 
for HPV 18/45 at 91% (95% CI: 59%, 100%) and lowest 
sensitivity for HPV 16 at 50% (95% CI: 16%, 84%).  
When restricting the analyses to women 
older than 30 years, based on current 
HPV testing guidelines, we found 
that there was increased sensitivity for 
detection of  all hr-HPV types combined, 
HPV 16 and additional hr-HPV, but a 
decrease in sensitivity for detection of  
HPV 18/45 (Table 4). The exclusion of  
younger women also led to an increase 
in most kappa values characterizing 
agreement between clinician and self-
collected samples, including for all 
categories of  hr-HPV (κ = 0.83), HPV 
16 (κ=0.85) and the additional hr-HPV 
category (κ=0.77). Restricting to older 
women (who are likely to have fewer 
transient infections) we found that 
in general there was increased kappa 
agreement and sensitivity although it 
was not consistent across all hr-HPV 
types.
Acceptability
Overall, women found the self-
collection procedure easy to perform (98%), reported that 
the instructions were easy to understand (100%), and were 
confident they did it correctly (95%; Table 5). Most women 
Data analysis
We first described the prevalence of  hr-HPV in the study 
population, overall and by the four separate GeneXpert result 
categories for both self- and clinician-collected samples. 
We then calculated the sensitivity and specificity of  self-
collected samples, using the clinician-collected samples as a 
reference standard. In order to assess agreement between the 
two sampling methods, we calculated a kappa statistic for 
overall hr-HPV type (positive for any hr-HPV vs. hr-HPV-
negative) and by the 3 GeneXpert hr-HPV categories (HPV 
16, HPV 18/45, additional hr-HPV types). As HPV testing 
is recommended only in women over 30 years of  age due to 
the transient nature of  HPV infections in younger women, 
we also conducted analyses restricting our sample to women 
over 30 years (n=126). Finally, using questionnaire data, 
we calculated frequencies to describe acceptability of  self-
collection among participants. All analyses were done using 
Stata 14.0 (StataCorp, College Station, TX). 
Ethical approval
This project received ethical approval from the Ohio State 
University Institutional Review Board and the University of  
Malawi College of  Medicine Research and Ethics Committee.
Results
Study population and prevalence of hr-HPV 
infections with clinician-collected sampling
We screened 234 women to enroll 200 in the parent study, 
199 of  whom consented to HPV testing.  Women without 
hr-HPV were slightly older than women with any hr-HPV 
(median age 34 vs. 32 years) and more likely to be married 
(97% vs. 77%; Table 1). Sixteen women (8%) were initially 
noted as having a positive VIA screen although two of  
these were later determined to be false positives. Of  the 
remaining 14 women, 10 presented with acetowhite lesions 
and four with inconclusive results that required additional 
screening. All 14 women were referred to the district hospital 
for additional screening and treatment as services were not 
available in the study clinic.
Among the women tested for HPV, 22% (n=43) had any 
The recently lowered costs of  HPV DNA testing may 
make this method of  cervical cancer screening a viable 
screening option in a wide variety of  settings. Combined 
with evidence that self-collection is a more effective way to 
screen women16–19, we aimed to evaluate how this method 
of  sample collection performed in a low-resource setting. 
Previous research suggests that many women in rural Malawi 
would be willing to self-collect a sample at home, yet no 
research has examined self-collection in a clinical setting or 
whether women’s hypothetical willingness would translate 
into actual behavior if  offered an opportunity to provide 
a self-collected sample. We sought to assess the validity, 
feasibility and acceptability of  using the GeneXpert HPV 
Assay to test self-collected vaginal samples in a rural clinic in 
Lilongwe District, Malawi. 
Methods 
Study setting and population
Women were recruited for this study as part of  a larger, 
clinic-based study examining sexual and reproductive 
tract infections. Briefly, from January to August 2015, any 
woman who presented to the study clinic in rural Lilongwe 
District, Malawi, with any genitourinary symptom (including 
abnormal menstrual cycle or patterns of  bleeding; pain 
with urination, pain during sex, abdominal pain, lower back 
pain, or any type of  pelvic pain; incontinence or unusual 
urine odour, frequency or colour; unusual vaginal discharge 
in terms of  quantity, odour, colour or consistency) was 
referred to study staff  to be assessed for eligibility. Women 
were eligible to participate if  they were 18-49 years of  age, 
spoke Chichewa, had at least one genitourinary symptom, 
consented to be examined and give biological specimens for 
testing, and resided in Lilongwe District. Women who were 
pregnant or menstruating were ineligible. Women provided 




Women were examined in a private clinic room by the study 
clinician. At the start of  the exam, each woman was offered 
the option to self-collect a vaginal sample for HPV testing. 
If  she agreed, she was given a sterile, cotton-tipped swab 
and instructions on how to collect the vaginal sample. The 
clinician remained in the study room, on the other side of  
a privacy screen, in case the participant had any questions 
about collecting the sample. After collection, the clinician 
placed the swab in 20 ml of  Preservcyt solution (Hologic, 
Bedford, Massachusetts) and proceeded to perform a pelvic 
examination. The clinician used an endocervical brush to 
collect the sample for HPV testing. Following collection, he 
swirled the cervical brush in 20 ml of  Preservcyt solution. 
Both clinician- and self-collected samples were stored 
between 2 and 8°C and were tested using the GeneXpert 
HPV assay at the end of  the study (Cepheid, Sunnyvale, 
California).  
The GeneXpert technology was developed to identify multi-
drug resistant tuberculosis, and WHO supported the roll-out 
of  GeneXpert systems for tuberculosis control programs in 
21 countries throughout Africa and Asia15. While HPV testing 
using the GeneXpert is a new application of  this technology, 
the GeneXpert platform is ubiquitous throughout Africa, 
including Malawi, and its use is supported by the Malawi 
Ministry of  Health. The GeneXpert HPV test yields results 
in four categories: (a) negative for hr-HPV; (b) positive for 
HPV16; (c) positive for HPV18 or 45; or (d) positive for one 
of  11 pooled hr-HPV types (31, 33, 35, 39, 51, 52, 56, 58, 59, 
66, and 68; Figure 1). The GeneXpert also includes quality 
assurance channels for sample adequacy control and a probe 
check control. 
All results from the HPV testing were recorded on paper 
forms and entered into an electronic spreadsheet by trained 
research staff. 
Questionnaire
After the clinical exam, the patient was sent to a separate 
study room where a research assistant, who did not provide 
clinical care, administered a brief  questionnaire capturing 
demographic characteristics and the acceptability of  the self-
collection procedure. The questionnaire included items about 
the ease of  collecting samples and understanding instructions, 
using a 5-point scale ranging from very easy to very difficult. 
Using the same scale, we also assessed women’s confidence 
in their ability to self-collect a sample, their preferences for 
collection of  samples for HPV testing, whether they would 
recommend self-collection to a friend, and concerns about 
self-collection. Questions were developed based on previous 
literature and work of  the study authors. All survey questions 
were recorded directly into the Magpi data collection system 
(Magpi, Washington, DC) and uploaded to an internet-based 
storage system daily. 
Testing of  clinician- and self-collected samples was not 
completed until the end of  the research study; therefore, 
we did not inform women if  they had hr-HPV. However, 
women found to have hr-HPV were referred to VIA, and 
all participants in the research study underwent VIA as part 
of  the research protocol. Treatment for abnormal lesions 
was not available at the study clinic, and thus women with 
abnormal VIA results were referred to secondary care 
at one of  two district hospitals in Lilongwe. The referral 
appointments were scheduled within a week of  the study 
visit, and participants were provided with funds to facilitate 
travel to and from Lilongwe. Study clinicians requested 
records documenting care received at the district hospitals. 
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reported they would recommend self-collection for HPV 
testing to a friend (99%) and more women preferred self-
collection compared to clinician-collection sampling (61% 
vs. 39%). 
Three-quarters of  women (74%) reported they would not 
have any concerns about self-collecting for HPV testing 
in the future. Among those who expressed concerns, 12% 
reported worries that self-swabbing might hurt, 11% feared 
the HPV results following self-collection might not be 
accurate, and 7% were concerned they may not test correctly.
Discussion
To our knowledge, this is the first study to examine self-
collected samples for HPV testing using the GeneXpert 
HPV assay in a low resource setting. Our findings suggest 
that self-collection of  samples for HPV testing is a feasible 
and acceptable method of  cervical cancer screening in this 
rural, Malawian population. While the specificity was high, 
we found lower levels of  sensitivity suggesting that self-
collected samples for HPV testing may not be as valid as 
clinician-collected samples. The self-collection procedure 
was easy to incorporate into the clinic setting with all but 
one participant providing a sample, and all collected samples 
were sufficient for testing. High agreement between the 
self- and clinician-collected samples, and high levels of  
acceptability among participants, suggest that self-collection 
procedures for HPV testing may be effectively incorporated 
into screening programs among rural, largely unscreened 
populations in Malawi.  
Using a new HPV DNA test, we found lower sensitivity 
but high agreement in HPV test results between self- and 
clinician-collected samples, in line with previous research on 
other tests from a range of  settings (kappa values ranging 
from 0.70-0.87)20–24. Our findings also align with previous 
research that suggests agreement in HPV results from self- 
and clinician-collected samples can vary by HPV type21. 
While the specificity of  the self-collected tests was very 
high in our study, sensitivity varied by type of  HPV. In other 
words, HPV testing using self-collected samples accurately 
detected HPV-negative women, but the ability to detect 
HPV-positive women using self-collected samples was more 
variable. When younger women were excluded from the 
sample, sensitivity was more comparable across the different 
types of  hr-HPV, although the sensitivity for detection of  
HPV 18/45 was slightly reduced. This overall pattern of  
lower sensitivity but higher specificity of  self-collected vs. 
clinician-collected samples is similar to findings from a study 
of  Gambian women, where self-collected samples had a 
sensitivity of  0.64 (95% CI: 0.52, 0.83) and specificity of  
0.94 compared to clinician-collected cervical samples25. 
Our findings suggest that self-collection of  samples for HPV 
testing was widely acceptable, easy to perform and preferred 
to clinician-collection. Combined with results from other 
research, our study provides evidence that self-collection 
could be used in an outreach capacity to increase screening 
in hard-to-reach populations. For example, among women 
in Argentina, women who were offered the opportunity to 
self-collect a sample in the home through community health 
workers were four times as likely to be screened for cervical 
cancer than women who were not offered the option to self-
collect15. In a randomized control trial conducted in Uganda, 
98% of  women in the HPV self-collection arm were screened 
for cervical cancer while in the control arm (VIA), only 48% 
of  women received cervical cancer screening26.
To be successfully implemented, screening programs using 
HPV testing will need to consider clinician and laboratory 
perspectives alongside other programmatic considerations. 
For example, in our project, the study clinician found that 
after a small number of  participants had enrolled, it was very 
simple to collect cervical samples using the cervical brush. 
On the other hand, he experienced challenges explaining the 
self-collection procedure to women, suggesting that a future 
screening program must provide detailed instructions or 
have present a healthcare provider to answer questions. The 
laboratory technician found it easy and fast to test samples 
using the GeneXpert HPV test. However, some samples 
required a repeat test due to machine error and added to 
costs of  HPV testing. We also experienced challenges in 
procuring the transport medium – an expensive part of  the 
testing procedure, and this supply issue must be addressed 
before a larger rollout of  any HPV testing program is 
possible in this region. Studies of  other polymerase chain 
reaction (PCR)-based HPV DNA tests suggest that more 
commercially-available and inexpensive transport media 
(e.g. Scope mouthwash27) or the collection and storage of  
dry samples, may perform comparably27,28, although to date 
these approaches have not been validated for the GeneXpert 
HPV DNA test. 
Our findings must be interpreted in light of  important study 
limitations. As our project was undertaken as a secondary 
arm of  a larger study, the population included younger 
women (under age 30) for whom HPV testing is not 
currently recommended. However, subgroup analyses with 
older women in the recommended range suggest that kappa 
of  self- and clinician-collected samples and sensitivity and 
specificity findings were valid for both groups. As this project 
was nested in a pilot study, we had a relatively small sample 
size, especially when excluding women under age 30. The 
smaller sample size may have influenced the lower sensitivity 
for self-collected samples. Generalizability of  our results 
may also be limited as we enrolled care-seeking women who 
presented with genitourinary symptoms to a medical facility. 
As HPV infections and early cervical lesions do not lead 
to noticeable symptoms, it will be important to determine 
whether HPV screening (via self-collected samples) remains 
acceptable in women without genitourinary symptoms. We 
also enrolled women presenting at a clinic, so we cannot 
extrapolate our results to cervical cancer screening programs 
in an outreach capacity. Additionally, our study clinician was 
in the room during self-collection of  the sample which may 
not be generalizable to an outreach setting where there are not 
trained personnel available. Our study also only assessed the 
feasibility of  self-collection compared to clinician-collected 
sampling, but we note that WHO guidelines recommend 
immediate treatment be available for any clinic-based cervical 
cancer screening program. Lastly, the acceptability questions 
may be influenced by response bias with participants voicing 
more favorable views on self-collection than they actually 
felt. We attempted to minimize this bias by having a non-
clinician research assistant deliver the questions in a separate, 
study room. 
While the rates of  cervical cancer incidence and mortality 
have decreased precipitously in the last 40 years globally, 
the burden of  disease falls disproportionally on women in 
low-resource settings without accessible screening programs. 
Although we have demonstrated some of  the utility of  
screening, Malawians remain with significant challenges in 
providing appropriate therapy in a reliable and sustainable 
way. While we did not deal with the whole scope of  
necessary care, we did assess one part of  the pathway, and 
demonstrated that it could be useful in the arc of  care that 
women need. 
Conclusion
Self-collecting samples for HPV testing has the potential 
to eliminate many of  the barriers of  other cervical cancer 
screening programs that restrict access for women in low-
resource settings. We submit that cervical cancer-screening 
programs using self-collected samples for HPV testing may 
be a feasible, valid, acceptable, and effective cervical cancer 
screening method in this rural Malawian population. 
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